- Theralase Technologies Inc (TSXV:TLT) has been granted a U.S. patent for Multiwavelength Photodynamic Therapy (PDT) technology.
- The patent will allow Theralase to use technology that may be help destroy large and/or deep-seated tumours.
- The company expects that the patent will increase the company’s value.
- Theralase Technologies’ share price is down 4.84 per cent, with shares trading at $0.30 apiece.
Pharmaceutical company Theralase Technologies Inc (TLT), has been granted a U.S. patent for Multiwavelength PhotoDynamic Therapy (PDT) technology.
The patent is entitled “Apparatus and Method for Multiwavelength Photodynamic Therapy”.
The patent grant will allow Theralase to use technology that may target and destroy large and/or deep-seated cancerous tumours more effectively.
The technology involves using various laser wavelengths to activate PhotoDynamic Compounds (PDC) in tumours.
The use of one particular laser wavelength often only partially destroys large and/or deep-seated tumours. However, the addition one or two more laser wavelengths may completely and safely destroy the tumours.
This is because different laser wavelengths can penetrate different tissue depths. Scientists believe that this will greatly aid in combatting cancers such as Glio Blastoma Multiform (GBM) and Non-Small Cell Lung Cancer (NSCLC).
Theralase’s Chief Scientific Officer, Dr Arkady Mandel M.D., Ph.D., D.Sc., predicts that the U.S. patent will increase company value.
The company’s comprehensive intellectual property portfolio will also continue to strengthen their position in the global oncology market.
Theralase Technologies’ share price is down 4.84 per cent, with shares trading at $0.30 apiece.
